(Q28246151)
Statements
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients (English)
0 references
January 2010
0 references
65
0 references
2
0 references
207-17
0 references
1 reference